secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2021-10-20T23:59:59+00:00
Accession:  0001558370-21-013308
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics appoints Matthias Alder as COO effective Oct 15, 2021
-----------------------------------------------------------------------

- Annual base salary of $400,000; eligible for 35% incentive target under management plan.
- Receives option grant of 200,000 shares with standard vesting and 200,000 RSUs tied to business/clinical milestones.
- Alder joins from Autolus Therapeutics where he was Chief Business Officer; previously EVP at Sucampo Pharmaceuticals.
- Appointment supports preparation for lead program in Gaucher and Parkinson's to enter clinical trials in 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000155837021013308/0001558370-21-013308-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000155837021013308/ganx-20211015x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-21-013308

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer